Transplant infectious disease specialists typically divide the post-transplant period into three roughly different intervals 131: (1) 1st month post-transplant, when infections are either a complication of the surgery/hospitalization or pre-existing in the donor or recipient; (2) one to six months post-transplant; this is the period when immunosuppression is definitely often the highest and opportunistic infections ( pneumonia, CMV or other herpes virus infections, mycobacterial infections, and so on) often happen, warranting prophylactic actions to prevent such infections; (3) after 6 to 12 months post-transplant, when immunosuppression is usually more stable and lower than in previous periods. This timeline is obviously altered by heightened immunosuppression due to rejection episodes. to PTDM development, changes in immunosuppression are limited by the higher risk of rejection with additional agents. Immunosuppression has also been implicated in higher risk of malignancy; therefore, proper tumor screening is needed. Tumor immunotherapy is definitely drastically changing the way particular types of malignancy are treated in the general human population; however, its use post-transplant is limited by the risk of allograft rejection. As expected, higher risk of infections is also experienced in transplant recipients. When caring for KT recipients, unique attention is needed in screening methods, preventive measures, and treatment of illness with BK disease and cytomegalovirus. Hepatitis C disease infection is definitely common in transplant candidates and in the deceased donor pool; however, newly developed direct-acting LDE225 Diphosphate antivirals have been proven safe and CDKN2A effective in the pre- and post-transplant periods. The most important and recent developments on complications following KT are examined in this article. gastric bypass) is definitely important because of an increased risk of urolithiasis, oxalate deposition in the kidney, and the potential (but not yet proven by appropriate, large pharmacokinetic studies) decreased LDE225 Diphosphate absorption of immunosuppressive medications 61, 64, 66, 67. Changes in immunosuppression should be based on overall patient and allograft benefit rather than on the risk of PTDM development only 46. Although tacrolimus has a higher risk of PTDM compared with cyclosporine A 42, 68, the former is LDE225 Diphosphate generally desired because of the lower risk of rejection and higher graft survival 69. The benefit of early corticosteroid withdrawal has been controversial; the largest randomized LDE225 Diphosphate trial found no difference in PTDM development at 5 years post-transplant with corticosteroid maintenance versus early withdrawal 70. This contrasts with the findings of an earlier meta-analysis that showed a reduced risk of PTDM with early steroid withdrawal but also an increased risk of allograft rejection 71. When steroid withdrawal is chosen, the PTDM incidence is similar if steroids are given for 10 days versus an intraoperative bolus only, but the incidence of rejection is definitely higher in the second group 72. Another potential strategy to decrease the risk of PTDM would be to use CNI-free regimens. Use of belatacept, a T-cell co-stimulation blocker, reduces the risk of PTDM by 39% compared with CNIs 73. Although mammalian target of rapamycin (mTOR) inhibitors are associated with a better glycemic profile than tacrolimus, they result in a worse lipid profile and higher rejection risk 42. Treatment of DM in the post-transplant period includes lifestyle changes with particular attention to healthy excess weight maintenance as well as pharmacologic therapy. Owing to the lack of evidence derived from well-designed prospective clinical trials investigating variations in hard medical end points such as mortality, allograft loss, and CV events in this human population, the optimal pharmacologic agent in transplant recipients is not well established 42. In the early post-transplant period, it is recommended to treat hyperglycemia with insulin since it is the safest and most effective agent in the context of high corticosteroid doses 46. Furthermore, this approach appears to reduce LDE225 Diphosphate the odds of developing PTDM by 73% in the 1st yr post-transplant 74. After corticosteroid doses are reduced, treatment with oral anti-hyperglycemic agents is recommended, but the choice of specific agent should be individualized. Because of a lack of evidence, the most recent consensus recommendations were unable to propose a hierarchy of anti-hyperglycemic providers for PTDM 46. The most commonly used anti-hyperglycemic medications post-transplant include metformin, sulfonylureas (that is, glipizide.